SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Characterized by a high percentage of bone marrow blasts without significant evidence of maturation to more mature neutrophils. Blasts constitute 90% or more of the non-erythroid cells. The myeloid nature of the blasts is demonstrated by MPO or SBB (>3% of blasts) positivity and/or Auer rods.
The provisional diagnoses during workup may include 1. AML without maturation 2. AML with maturation 3. Acute lymphoblasticleukemia (ALL)